Invivyd's candidate had fewer short-term side effects than the vaccine alone, and combined use raised antibody levels. But the study did not test illness prevention, and FDA approval is not yet granted.
These findings give Invivyd a clearer path to seek U.S. approval. Fewer short-term side effects than the vaccine alone and higher antibody levels with combined use support the candidate's potential. The study did not test whether the drug prevents illness, and FDA approval has not been granted. Invivyd says it will continue a later study to check whether the drug works.
Pfizer's Comirnaty vaccine was tested alone and with Invivyd's candidate. The report gives no news about a change to Pfizer's own business outlook.
BioNTech's Comirnaty vaccine was tested alone and with Invivyd's candidate. The report gives no news about a change to BioNTech's own business outlook.
Follow Invivyd Inc. (IVVD) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for IVVD